The pharmaceutical companies Biogen and Eisai are developing a new drug to slow the rate of cognitive decline among patients with Alzheimer's disease, according to the New York Times. The drug, called lecanemab, reduced cognitive decline by 27 percent in a recent clinical trial. Previously, Biogen released the controversial drug Aduhelm, widely considered a commercial failure after Medicare restricted its coverage.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
